These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17198587)

  • 1. [A meta-analysis of the curative effects of carboplatin-based and cisplatin-based chemotherapeutic regimens on advance non-small cell lung cancer].
    Jiang JW; Liang XH; Zhou XL; Huang RF
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(37):2615-20. PubMed ID: 17198587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX; Chen XB
    Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
    Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
    J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
    D'Addario G; Pintilie M; Leighl NB; Feld R; Cerny T; Shepherd FA
    J Clin Oncol; 2005 May; 23(13):2926-36. PubMed ID: 15728229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
    Selvaggi G; Belani CP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
    McCulloch M; See C; Shu XJ; Broffman M; Kramer A; Fan WY; Gao J; Lieb W; Shieh K; Colford JM
    J Clin Oncol; 2006 Jan; 24(3):419-30. PubMed ID: 16421421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin doublets in non-small cell lung cancer: a literature review.
    Cortinovis D; Bidoli P; Zilembo N; Fusi A; Bajetta E
    Lung Cancer; 2008 Jun; 60(3):325-31. PubMed ID: 18440088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
    Früh M; Rolland E; Pignon JP; Seymour L; Ding K; Tribodet H; Winton T; Le Chevalier T; Scagliotti GV; Douillard JY; Spiro S; Shepherd FA
    J Clin Oncol; 2008 Jul; 26(21):3573-81. PubMed ID: 18640938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?
    Tiseo M; Boni L; Ardizzoni A
    J Clin Oncol; 2005 Sep; 23(25):6276-7; author reply 6277-8. PubMed ID: 16135504
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
    Rajeswaran A; Trojan A; Burnand B; Giannelli M
    Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms.
    Socinski MA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4210s-4214s. PubMed ID: 15217960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
    Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
    J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical advances in the chemotherapy of non-small cell lung cancer].
    Liao ML; Cheng BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jul; 27(7):480-2. PubMed ID: 15312563
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant chemotherapy in resected non-small cell lung cancer.
    Cangiano R
    Rays; 2004; 29(4):435-7. PubMed ID: 15852732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoradiation paradigm for the treatment of lung cancer.
    Eberhardt W; Pöttgen C; Stuschke M
    Nat Clin Pract Oncol; 2006 Apr; 3(4):188-99. PubMed ID: 16596143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.